No type of this prior therapy other than surgery is allowed. Study entry will depend upon the time lapsed since the day of the surgical procedure. Treatment will consist of a combination of a new drug, DaunoXone, with dexamethasone. Patients responding to this therapy will go on to receive a maintenance therapy with Interferon Alpha-2b. Patients who are candidates for stem cell transplantation would not be eligible for this study.
Antibodies are small proteins which target special markers on the surface of certain types of cells.
The antibodies in this treatment are designed to attach to the lymphoma cells and deliver a small molecule of radioactive iodine to kill the lymphoma cell. As a part of the eligibility requirement, the patient's bone marrow will be analyzed to determine whether tumor is present and whether the Lym-1 antibody attaches to the lymphoma cells. Lym-1 therapy requires hospitalization for three to five days for a period of approximately four months. Patients must have relapsed or be refractory to chemotherapy or radiation therapy. Exclusion criteria include primary CNS lymphoma, history of pancreatitis, previous series allergic reactions or history of non-iatrogenic bleeding diathesis.